Published Date: Apr 09 2026
Collagen makes up about 30% of the total protein in the human body (Aladdin Sci, 2025). This protein serves as the main building block of skin, bones, tendons, and connective tissues. It gives skin its strength, flexibility, and ability to heal. As people age, the body's natural collagen production slows down. This slowdown leads to wrinkles, sagging skin, and slower wound healing.
Medical device-grade recombinant humanized collagen offers a solution to these age-related changes. Unlike traditional collagen sourced from animals, recombinant humanized collagen is made through genetic engineering. This method produces collagen that closely matches the collagen naturally found in human skin. The result is a material with lower immune response risk and better biocompatibility.
Zhuhai Gene-Biocon Biological Technology Co., Ltd. (Hereinafter referred to as: GENE-BIOCON) has developed three types of medical device-grade recombinant humanized collagen: Type I, Type III, and Type XVII. Each type serves a distinct purpose in aesthetic medicine and skin repair.
Type I Collagen: The Structural Foundation
Type I collagen provides the main mechanical support to the dermis (Li et al., 2025). This type of collagen forms thick, strong fibers in the deeper layers of the skin. It acts like a structural framework that holds the skin up and keeps it firm. Without enough Type I collagen, skin loses its tightness and begins to sag. In aesthetic medicine, Type I collagen is used to restore volume, improve skin firmness, and reduce deep wrinkles.
Type III Collagen: The Repair Specialist
Type III collagen enhances skin elasticity and helps with barrier repair (Li et al., 2025). This collagen type forms thinner, looser fibers arranged in a mesh-like network near the surface of the skin (Aladdin Sci, 2025). In infants, Type III collagen makes up about 60% of the collagen in the skin. In adults, this number drops to about 20%. The body cannot make new Type III collagen after adulthood. This decline explains why adult skin takes longer to heal and loses its softness over time.
Type III collagen plays a critical role in wound healing. It helps build new extracellular matrix in the early phase of skin injury. A higher proportion of Type III collagen leads to repair tissue that looks more like normal skin (Aladdin Sci, 2025). Too little Type III collagen often results in rigid scar formation.
GENE-BIOCON's recombinant Type III humanized collagen carries the medical device master file registration number M2025132-000. The company uses AI algorithms and molecular dynamics simulation to create the "golden triple helix structure" of this medical-grade collagen. This technology improves product stability by four times and lowers degradation risk by 76% (GENE-BIOCON, 2025).
Type XVII Collagen: The Stem Cell Regulator
Type XVII collagen regulates the homeostasis of epidermal stem cells (Li et al., 2025). Unlike Type I and Type III, which are structural collagens, Type XVII is a transmembrane protein. It anchors the epidermis to the dermis by connecting intracellular keratin networks to extracellular laminin-332 (NIKOO Chemical, 2025). This anchoring function keeps the skin layers firmly attached and stable.
Type XVII collagen also plays a key role in hair follicle health. It anchors hair follicle stem cells via hemidesmosomes and prevents these cells from dying under oxidative stress (NIKOO Chemical, 2025). Loss of Type XVII collagen is one of the triggers for hair follicle shrinkage and hair loss. More than 2.5 billion people worldwide experience hair loss, and current treatments offer limited results. Type XVII collagen provides a new biological approach to this widespread problem.
Why Medical Device-Grade Matters
The term "medical device-grade" refers to materials that meet strict regulatory standards. In China, the National Medical Products Administration (NMPA) has issued guidelines for recombinant collagen biomaterials used in medical devices (NMPA, 2021). These guidelines classify recombinant collagen into three categories based on protein composition and structure. Medical device-grade materials must pass rigorous tests for purity, sterility, and biological safety.
GENE-BIOCON's Type III humanized collagen meets these high standards. The product specifications show a purity of 95% or higher. The bacterial endotoxin level is less than 0.5 EU/mg. The residual host cell protein is 0.05% or less. These numbers mean the material is safe for use on damaged skin and open wounds.
Applications in Aesthetic Medicine
Medical device-grade recombinant humanized collagen has many uses in aesthetic medicine.
Post-procedure recovery. Laser treatments, chemical peels, and microneedling all damage the skin barrier. After these procedures, the skin needs help to heal quickly and without scarring. Recombinant collagen dressings and sprays provide this help. They supply the building blocks the skin needs to repair itself.
Wound care for non-chronic wounds. Medical device-grade collagen is approved for use on superficial wounds, surgical incisions, small cuts, and scrapes. The collagen creates a moist healing environment and gives cells a scaffold on which to grow.
Anti-aging treatments. As people age, their skin loses both Type I and Type III collagen. Topical and injectable forms of recombinant collagen can supplement what the body no longer makes. This supplementation helps reduce fine lines, improve skin texture, and restore a more youthful appearance.
Scalp and hair health. Type XVII collagen offers a new way to support hair follicle health. By stabilizing the dermo-epidermal junction and protecting stem cells, this collagen type may help slow or reverse some forms of hair loss.
The Future of Collagen-Based Aesthetic Medicine
The recombinant humanized collagen market is growing quickly. Advances in stable production and custom design have made this material available for high-end medical devices, functional skincare products, and tissue regeneration (Xinhua Net, 2025). As more products receive regulatory approval, patients will have access to safer and more effective collagen-based treatments.
GENE-BIOCON continues to lead in this field. The company owns a 4,000-square-meter GMP-certified production facility. Its five technology platforms cover gene expression, fermentation, enzyme production, nucleic acid tools, and transdermal absorption (GENE-BIOCON, 2025). With more than 28 patents and business in over 50 countries, GENE-BIOCON provides complete solutions for brands seeking medical-grade collagen materials.
The shift from animal-derived to recombinant collagen is a major step forward for aesthetic medicine. Patients no longer have to accept the risks of immune reactions or inconsistent quality. Medical device-grade recombinant humanized collagen delivers predictable, safe, and effective results. For doctors and patients alike, this material represents a new standard of care.
Works Cited
Aladdin Sci. "Recombinant Humanized Type III Collagen: Structural Basis, Manufacturing Technologies, and Dermatological Applications." Aladdin Scientific, 2025, www.aladdinsci.com/faqs/recombinant-humanized-type-iii-collagen-en.html.
GENE-BIOCON. "Recombinant Type III Humanized Collagen." GENE-BIOCON Biotechnology, 2025, zhuhaigbc.com/products/cosmetic_raw_materials/patented_proteins/recombinant_humanized_cllagen_type_3.html.
GENE-BIOCON. "About Us." GENE-BIOCON Biotechnology, 2025, www.zhuhaigbc.com/index.php?c=category&id=1.
Li, Yaru, et al. "Roles of Different Types of Collagen in Skin Aging and Their Research Progress." Sheng Wu Gong Cheng Xue Bao, vol. 42, no. 2, 2025, pp. 533-546. PubMed, doi:10.13345/j.cjb.250472.
NIKOO Chemical. "Let You Know Recombinant Humanized Type XVII Collagen Well." NIKOO Chemical, 2025, www.nikoochem.com/let-you-know-recombinant-humanized-type-xvii-collagen-well.html.
NMPA. "Interpretation of the Guiding Principles for Naming Recombinant Collagen Biomaterials." National Medical Products Administration, 2021, www.nmpaied.org.cn/gyy/zhengcefagui/zhengcejiedu/465774481286238208.html.
Xinhua Net. "Recombinant Humanized Collagen Scales Up for Wider Use; Experts Answer Questions." Xinhua News Agency, 2025, www.sx.xinhuanet.com/20250709/90ce933379c54287a36b23eb8eccb51e/c.html.
